Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
Mak, Gabriela; Arkenau, Hendrik-Tobiasb; Chin, Melvina
aMedical Professorial Unit, Prince of Wales Hospital and University of New South Wales, Randwick, New South Wales, Australia
bSarah Cannon Research UK and University College London, London, UK
Correspondence to Gabriel Mak, MBBS, Medical Professorial Unit, Prince of Wales Hospital, University of New South Wales, Edmund Blackett Building, 1st Floor, South Wing, Randwick 2031, NSW, Australia Tel: +61 401 132 487; e-mails: email@example.com
This is an open-access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.
Received November 28, 2013
Accepted April 1, 2014
Treatment responses of BRAF mutant melanoma to BRAF inhibitors are often limited by the development of resistance. This case report describes the use of multiplatform molecular profiling in sequential surgical samples of a treatment-resistant tumour site subjected to ongoing treatment with dabrafenib in a patient with metastatic cutaneous BRAF mutant melanoma. Next-generation sequencing showed the presence of the V600E, fibroblast growth factor receptor 2 (FGFR2), phosphatase and tensin homologue (PTEN) and p53 gene mutations. With a continuous presence of the BRAF V600E, FGFR2 and PTEN mutations and appearances of new mutations in the PTEN gene at R137H and T321fs and p53 R273C genes during ongoing treatment, this case report indicates intratumoural clonal evolution as a resistance mechanism. Two new mutations, the G542E exon 12 mutation variant of the FGFR2 gene and the R273C mutation variant of the p53 gene, are reported for the first time in BRAF mutant melanoma.
Treatment of metastatic v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) mutant cutaneous melanoma has been revolutionized with the use of drugs targeting the mitogen-activated protein kinase (MAPK) pathway. Although survival is improved, resistance typically occurs within 5 to 7 months for patients treated with single-agent BRAF or mitogen-activated protein kinase kinase (MEK) inhibitors, and 9.4 months with a BRAF/MEK combination 1–3. In this context, multiple mechanisms of adaptive resistance have been reported. Molecular profiling technologies have widely become available, allowing for the use of genome sequencing, immunohistochemical (IHC) analysis and in-situ hybridization techniques to help identify individual biomarkers within tumours for clinical application.
We report a case of a patient with metastatic cutaneous BRAF mutant melanoma treated with dabrafenib who underwent repeat debulking surgery for a resistant lesion while disease in other metastatic sites was controlled. Molecular profiling was performed on metachronous resected tumour samples, providing an insight into the molecular changes between samples.
In 1995, a 22-year-old man underwent completely resection of a localized cutaneous melanoma in the neck. He was diagnosed in September 2008 with a lytic lesion in the left eighth rib, a soft tissue mass invading the transverse process and pedicle of the left fourth lumbar vertebra (L4) and a nodule inferior to the right lung hilum. These lesions were intensely FDG-PET avid. The lesions in the rib and L4 were surgically removed in November 2008 and confirmed to be metastatic melanoma. Postoperative radiotherapy was administered to L4. A month later, the lung nodule was resected and treated with radiotherapy. In March 2009, new disease was detected in the right upper lobe of the lung and manubrium. In addition, residual PET avid disease was seen in the right hilum and the L4 region (SUVmax 7.0).
The resected right hilar lymph node was tested for the BRAF mutation by Sanger sequencing. This showed the presence of a V600E mutation in exon 15 of the BRAF gene. On the basis of this, he enrolled in a phase I clinical trial in July 2009 and received dabrafenib 100 mg t.d.s. The sites of disease recorded at enrolment were the lesions at L4, manubrium and lung. The patient tolerated dabrafenib without significant side effects. A PET scan in September 2009 showed resolution of the manubrial lesion and less PET avidity in the L4 lesion (SUVmax 5.5). A further PET scan in November 2009 showed further decrease in avidity of the L4 lesion (SUVmax 5.2) and no evidence of new metastases.
In late 2010, the patient complained of paraesthesia along the left L4 dermatome. Investigations indicated a shape change in the L4 lesion and no other sites of active disease. After discussion between the clinical trial and surgical teams, a second debulking procedure was performed in January 2011 after 18 months on dabrafenib. Dabrafenib was briefly suspended for the operation and recommenced postoperatively. In March 2012, scans indicated disease progression at the L4 site and a third surgical procedure by an anterior approach was performed. Optimal debulking was not achieved and in July 2012, further debulking was done by the posterior approach. He received postoperative radiotherapy. Subsequently, the patient had symptoms of L5 nerve root compression and another debulking procedure of the persistent residual L4 soft tissue mass was performed in April 2013. Dabrafenib was continued throughout on the basis that it continued to suppress other metastatic disease. He subsequently received the dabrafenib–trametinib combination, but this failed to stop disease progressing at L4 and he underwent a final debulking procedure in August 2013. Postoperatively, he received ipilimumab (Table 1).
We performed molecular profiling (Caris Life Sciences Phoenix, Arizona, USA) on four surgical specimens from the recurrently progressing L4 metastatic site – November 2008, January 2011, March 2012 and April 2013 (Table 2). Platforms used included next-generation sequencing, protein expression IHC analysis, and fluorescence and chromogenic in-situ hybridization techniques. Written informed consent was obtained from the patient for publication of this case report.
Topoisomerase 2A staining was positive throughout all four samples. The secreted protein acidic and rich in cysteine (SPARC) protein was positive in the first and third sample, topoisomerase 1 was only positive in the second and third samples, whereas O-6-methylguanine-DNA methyltransferase (MGMT) staining was positive in the first and fourth samples. P-glycoprotein expression was stained positive in the first sample, thymidylate synthase staining was positive in the first three samples and cMET (tyrosine kinase receptor for hepatocyte growth factor and scatter factor) showed positive staining only in the last sample. Other IHC biomarkers stained negatively throughout the samples. Changes in staining intensity were observed for the phosphatase and tensin homologue (PTEN).
Human epidermal growth factor receptor 2 (HER2/Neu) was undetectable by chromogenic in-situ hybridization throughout all four samples (Table 2).
Detectable mutations have been reported with the alteration frequency – being the ratio between mutation and wild-type genes. The patient’s tumour showed the BRAF V600E mutation throughout as well as mutations of the fibroblast growth factor receptor 2 (FGFR2) (G542E exon 12) and PTEN (K267fs exon 12) genes. During the treatment, a new PTEN mutations (R137H in exon 6, third sample, and T321fs in exon 8, fourth sample) occurred. New tumour suppressor p53 (TP53) gene mutations were detected in the third and fourth sample (Table 2).
In patients with BRAF V600 mutant melanoma, multiple diverse mechanisms of primary and acquired resistance have been described as a result of treatment with BRAF inhibitors. These aberrations can occur at multiple levels of the MAPK pathway, as well as bypass signalling pathways (Fig. 1) 4–7.
Alterations upstream of BRAF can maintain the MAPK pathway signalling through the neuroblastoma RAS viral oncogene homologue gene (NRAS) proto-oncogene c-RAF (CRAF) signalling axis 8. Downstream of BRAF, mutations in MEK1 can cause reactivation of the MAPK pathway in the presence of BRAF inhibition 9,10. At the level of BRAF, multiple abnormalities have been identified, namely, BRAF amplification, gain of BRAF copy numbers 11, truncation of BRAF (p61 BRAF V600E) 12 and overactivity of CRAF and COT/Tpl2 13. Other resistance mechanisms include signalling through the tyrosine kinase receptors of the insulin-like growth factor 1 and platelet-derived growth factor receptor-β.
The persistence of the V600E mutation in all samples of our patient is consistent with the reported molecular analyses from the pivotal vemurafenib studies, which showed that tumours that developed acquired resistance maintained their V600 mutations 14.
The phosphoinositide kinase/protein kinase B/mammalian target of the rapamycin (PI3K/AKT/mTOR) axis has been described as one of the most prominent bypass signalling pathways accounting for ∼20% of resistance 15. In this context, loss of function of the tumour suppressor gene PTEN has been described and associated with resistance and shorter progression-free survival 16. In our patient, we detected the K267fs PTEN mutation in exon 12 throughout, but also found new mutations in exon 6 (R137H) and exon 8 (R273C), respectively. On a protein level, IHC staining was negative in all four samples, indicating loss of function of PTEN.
Recent evidence suggests that enhanced activation of FGFR is linked to Ras and MAPK activation, therefore conferring resistance to BRAF inhibitors 17. In this context, overexpression of FGFR2 and FGFR3 through autocrine feedback loops has been identified as one of the key signalling mechanisms. Interestingly, however, there are now emerging data that FGFR2 mutations may result in receptor loss of function through several distinct mechanisms, including loss of ligand binding affinity, impaired receptor dimerization, destabilization of the extracellular domains and reduced kinase activity 18. Whether our newly described FGFR2 exon 12 mutation falls into this category needs to be investigated further.
The inactivation of the p53 tumour suppressor pathway, which often occurs through mutations in TP53, is common in human cancers, but rare in melanoma (3–5%) 18–20. Inactivation of p53 signalling can be a result of various mechanisms such as mutation or deletion of TP53, inactivation of ATM, amplification of MDM2, expression of viral oncoproteins or alteration in cofactors or downstream effectors which, in turn, can lead to enhanced growth and genomic instability. The appearance of the exon 8 R273C mutation in the third and fourth sample may have contributed towards further genomic instability and subsequent progression.
A recent report by Romano et al. 21 supports our findings showing the coexistence of different molecular mechanisms of resistance to BRAF inhibition. In this case study, molecular profiling was performed on pretreatment tumour and two subcutaneous metastases: one that was present at baseline and responded to vemurafenib and a second site that occurred after reintroduction of vemurafenib. The genetic alterations detectable in the two metastatic sites were tumour specific, mutually exclusive and not detectable in the pretreatment tumour 21.
Our patient is currently being treated with the CTLA-4 monoclonal antibody ipilimumab, and in case of disease progression, we are planning to rebiopsy and repeat molecular profiling to track potential new changes, which may guide us for further management. With emerging new drug therapies and combination strategies for patients with BRAF mutant melanoma, this report highlights the usefulness for serial/longitudinal biopsies to monitor disease response/progression and select patients for appropriate clinical trials.
The cost of testing for one specimen was funded by the patient. Caris Life Sciences provided complimentary testing of three other samples; and the cost of enabling open access.
Conflicts of interest
There are no conflicts of interest.
1. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al..Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med2012;367:1694–1703.
2. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al..Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med2012;366:707–714.
3. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al..Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Lancet2012;380:358–365.
4. Lemech C, Infante J, Arkenau HT.Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.Drugs2013;73:767–777.
5. Salama AKS, Flaherty KT.BRAF in melanoma: current strategies and future directions.Clin Cancer Res2013;19:4326–4334.
6. Fedorenko IV, KHT Paraiso, KSM Smalley.Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Biochem Pharmacol2011;82:201–209.
7. Pritchard AL, Hayward NK.Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance.Clin Cancer Res2013;19:2301–2309.
8. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al..Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation.Nature2010;468:973–977.
9. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al..MEK1 mutations confer resistance to MEK and B-RAF inhibition.Proc Natl Acad Sci USA2009;106:20411–20416.
10. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al..Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.J Clin Oncol2013;31:1767–1774.
11. Shi H, Moriceau G, Kong X, Lee M-K, Lee H, Koya RC, et al..Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance.Nat Commun2012;3:724.
12. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al..RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E).Nature2011;480:387–390.
13. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al..Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.Cancer Res2008;68:4853–4861.
14. McArthur G, Ribas A, Chapman P, Flaherty K, Kim K, Puzanov I, et al..Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).J Clin Oncol2011;29526s, (Suppl; abstr 8502).
15. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al..Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.Cancer discov2014;4:80–93.
16. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D’Andrea K, et al..Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).Clin Cancer Res2013;19:4868–4878.
17. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al..Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.J Biol Chem2012;287:28087–28098.
18. Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, et al..Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.Mol Cancer Res2009;7:41–54.
19. Jochemsen AG.Reactivation of p53 as therapeutic intervention for malignant melanoma.Curr Opin Oncol2014;26:114–119.
20. Carson C, Omolo B, Chu H, Zhou Y, Sambade MJ, Peters EC, et al..A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.Pigment Cell Melanoma Res2012;25:514–526.
21. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, et al..Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Clin Cancer Res2013;19:5749–5757.
metastatic melanoma; molecular profiling; treatment resistance
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
Highlight selected keywords in the article text.